

Fig. (5). Concept of selective visualization of lymph node metastasis with Telomelysin-GFP.

respectively, which are sufficiently reliable to support the concept of this approach [99]. These data indicate that Telomelysin-GFP causes viral spread into the regional lymphatic area and selectively replicates in neoplastic lesions, resulting in GFP expression in metastatic lymph nodes (Fig. 5). This experiment mimics the clinical scenario where patients with gastrointestinal malignancies and lymph node metastasis undergo surgery, and the data suggest that the surgeon can identify metastatic lymph nodes by illuminating the abdominal cavity with a Xenon lamp.

Administration of Telomelysin-GFP offers an additional advantage in cancer therapy. Telomelysin-GFP, similar to Telomelysin, is an oncolytic virus, and selectively kills human tumor cells by viral replication; the process of cell death by Telomelysin-GFP, however, is relatively slow compared to apoptosis-inducing chemotherapeutic drugs, because the virus needs time for replication. Therefore, tumor cells infected with Telomelysin-GFP express GFP fluorescence, followed by loss of viability, allowing the timing of detection. Thus, Telomelysin-GFP can spread into the regional lymph nodes after intratumoral injection, express GFP signals in tumor cells by virus replication, and finally kill tumor cells even if the surgeon failed to remove all nodes containing micrometastasis.

CONCLUSION AND PERSPECTIVES

There have been very impressive advances in our understanding of the molecular aspects of human cancer and in the development of technologies for genetic modification of viral genomes. Nevertheless, there are many remaining hurdles, ethical and technical that must be solved before virotherapy including virus-mediated gene therapy ever reach routine clinical application. The safety considerations in the virus manufacture and clinical protocols are among the most important issues to be studied. Another important issue is to find ways to selectively deliver viruses into a high percentage of malignant cells in an existing tumor mass. The use of tissue or cell-type specific promoters could perhaps achieve

specificity of virus-mediated antitumor effect. The hTERT promoter-based transcriptional targeting in adenoviral constructs is a powerful tool for cancer diagnosis and therapy. In particular, the hTERT-specific oncolytic adenovirus achieves a more strict targeting potential due to the amplified effect by viral replication, and is a promising therapeutic alternative to replication-deficient gene therapy vectors. Several independent studies that used different regions of hTERT promoter and different sites of adenoviral genome responsible for viral replication, have shown that the hTERT promoter allows adenoviral replication as a molecular switch and induces selective cytopathic effect in a variety of human tumor cells [70-72, 74]. Among these viral constructs, to the best of our knowledge, Telomelysin seems to be the first hTERT-dependent oncolytic adenovirus that has been used in a clinical trial based on preclinical pharmacological and toxicological studies.

Although Telomelysin showed a broad and profound antitumor effect in human cancer originating from various organs, one weakness of Telomelysin is that virus infection efficiency depends on CAR expression, which is not highly expressed on the cell surface of some types of human cancer cells. Thus, tumors that lost CAR expression may be refractory to infection with Telomelysin. Since modification of fiber protein is an attractive strategy for overcoming the limitations imposed by the CAR dependence of Telomelysin infection, we modified the fiber of Telomelysin to contain RGD (Arg-Gly-Asp) peptide, which binds with high affinity to integrins ($\alpha v \beta 3$ and $\alpha v \beta 5$) on the cell surface, on the HI loop of the fiber protein (Fig. 2). The resultant adenovirus, termed Telomelysin-RGD or OBP-405, mediated not only CAR-dependent virus entry but also CAR-independent, RGD-integrin-dependent virus entry [75]. Telomelysin-RGD had an apparent oncolytic effect on human cancer cell lines with low CAR expression. Intratumoral injection of Telomelysin-RGD into CAR-negative tumor xenografts in mice resulted in significant inhibition of tumor growth and long-term survival. These data suggest that fiber-modified Telomelysin-RGD exhibits a broad target ranges by increasing infection efficiency, although one needs to be

cautious about increased toxicity since hematopoietic cell population such as dendritic cells can be efficiently infected with RGD-modified adenovirus [100].

A possible future direction for Telomelysin includes combination therapy with conventional therapies such as chemotherapy, radiotherapy, surgery, immunotherapy, and new modalities such as antiangiogenic therapy. Since clinical activities observed by intratumoral injection of Telomelysin suggest that even partial elimination of the tumor could be clinically beneficial, the combination approaches may lead to the development of more advanced biological therapy for human cancer. The combination of systemic chemotherapy and local injection of Telomelysin has been shown to be effective as described above [77]. In addition, we found that oncolysis induced by Telomelysin infection could be the most effective stimulus for immature dendritic cells to induce specific activity against human cancer cells. Therefore, Telomelysin can be effective not only as a direct cytotoxic drug but also as an immunostimulatory agent that induces specific cytotoxic T-lymphocytes (CTL) for the remaining antigen-bearing tumor cells. Peri- or postoperative administration of Telomelysin may be also valuable as adjuvant therapy in areas of microscopic residual disease at tumor margins to prevent recurrence or regrowth of tumors.

To our knowledge, no experimental viral agents that target human cancer including gene therapy products have been clinically approved in the world except in China. Advexin, which delivers normally functioning p53 tumor suppressor gene to cancer cells, will most likely be the first gene therapy drug approved in the US; the clinical development phase of Advexin, however, may be more than 10 years from the year the clinical study was initiated. The transition from phase I to phase III is also necessary for the development of Telomelysin. The recent surge in the approval rate for therapeutic monoclonal antibodies that were unsuccessful in the early 1980s is encouraging. Once one or more viral agents are approved in the US, the clinical development of oncolytic viruses is expected to move rapidly to the market.

The field of virotherapy is progressing considerably and is rapidly gaining medical and scientific acceptance. Although many technical and conceptual problems await to be solved, ongoing and future clinical studies will no doubt continue to provide important clues that may allow substantial progress in human cancer therapy.

ACKNOWLEDGEMENTS

This work was supported in part by Grants-in-Aid from the Ministry of Education, Science, and Culture, Japan; and Grants from the Ministry of Health and Welfare, Japan. We thank Drs. Hitoshi Kuwamura and Katsuyuki Nagai (Oncolys BioPharma, Inc.) for helpful discussions at all stages of this work.

ABBREVIATIONS

AFP	=	α - Fetoprotein
CAR	=	Coxsackie's-adenovirus receptor
CCD	=	Cooled charged-coupled device
CMV	=	Cytomegalovirus
COX	=	Cyclooxygenase

CT	=	Computed tomography
CTL	=	Cytotoxic T-lymphocytes
EGF	=	Epidermal growth factor
ERE	=	Estrogen response element
FDA	=	Food and Drug Administration
FDG	=	^{18}F -2-deoxy-D-glucose
GFP	=	Green fluorescent protein
HDAC	=	Histone deacetylase
HPV	=	Human papilloma virus
hTERT	=	Human telomerase reverse transcriptase
LC3	=	Light chain 3
MOI	=	Multiplicity of infection
MRI	=	Magnetic resonance imaging
MZF-2	=	Myeloid-specific zinc finger protein 2
NIH	=	National Institutes of Health
NSAID	=	Nonsteroidal anti-inflammatory drug
PET	=	Positron emission tomography
PSA	=	Prostate-specific antigen
RAC	=	Recombinant DNA Advisory Committee
TSA	=	Tricostatin A
WT1	=	Wilm's tumor suppressor 1

REFERENCES

- [1] Collins, K. Mammalian telomeres and telomerase. *Curr. Opin. Cell Biol.* 2000, 12, 378-383.
- [2] Blackburn, E. H. Switching and signaling at the telomere. *Cell* 2001, 106, 661-673.
- [3] Aviv, A.; Aviv, H. Telomeres, hidden mosaicism, loss of heterozygosity, and complex genetic traits. *Hum. Genet.* 1998, 103, 2-4.
- [4] Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. *Cell* 2000, 100, 57-70.
- [5] Vogelstein, B.; Kinzler, K. W. The multistep nature of cancer. *Trends Genet.* 1993, 9, 138-141.
- [6] Wright, W. E.; Shay, J. W. Telomere dynamics in cancer progression and prevention: fundamental differences in human and mouse telomere biology. *Nat. Med.* 2000, 6, 849-851.
- [7] Counter, C. M. The roles of telomeres and telomerase in cell life span. *Mutat. Res.* 1996, 366, 45-63.
- [8] Morin, G. B. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. *Cell* 1989, 59, 521-529.
- [9] Collins, K.; Mitchell, J. R. Telomerase in the human organism. *Oncogene* 2002, 21, 564-579.
- [10] Nugent, C. I.; Lundblad, V. The telomerase reverse transcriptase: components and regulation. *Genes Dev.* 1998, 12, 1073-1085.
- [11] Kim, N. W.; Piatyszek, M. A.; Prowse, K. R.; Harley, C. B.; West, M. D.; Ho, P. L.; Coviello, G. M.; Wright, W. E.; Weinrich, S. L.; Shay, J. W. Specific association of human telomerase activity with immortal cells and cancer. *Science* 1994, 266, 2011-2015.
- [12] Shay, J. W.; Bacchetti, S. A survey of telomerase activity in human cancer. *Eur. J. Cancer* 1997, 33, 787-791.
- [13] Blackburn, E. H. Telomere states and cell fates. *Nature* 2000, 408, 53-56.
- [14] Dong, C. K.; Masutomi, K.; Hahn, W. C. Telomerase: regulation, function and transformation. *Crit. Rev. Oncol. Hematol.* 2005, 54, 85-93.
- [15] Shay, J. W.; Wright, W. E. Telomerase: a target for cancer therapeutics. *Cancer Cell* 2002, 2, 257-265.
- [16] Feng, J.; Funk, W. D.; Wang, S. S.; Weinrich, S. L.; Avilion, A. A.; Chiu, C. P.; Adams, R. R.; Chang, E.; Allsopp, R. C.; Yu, J. The RNA component of human telomerase. *Science* 1995, 269, 1236-1241.
- [17] Harrington, L.; McPhail, T.; Mar, V.; Zhou, W.; Oulton, R.; Bass, M. B.; Arruda, I.; Robinson, M. O. A mammalian telomerase-associated protein. *Science* 1997, 275, 973-977.
- [18] Meyerson, M.; Counter, C. M.; Eaton, E. N.; Ellisen, L. W.; Steiner, P.; Caddle, S. D.; Ziaugra, L.; Beijersbergen, R. L.; Davidoff, M. J.; Liu, Q.

- Bacchetti, S.; Haber, D. A.; Weinberg, R. A. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. *Cell* 1997, 90, 785-795.
- [19] Nakamura, T. M.; Morin, G. B.; Chapman, K. B.; Weinrich, S. L.; Andrews, W. H.; Lingner, J.; Harley, C. B.; Cech, T. R. Telomerase catalytic subunit homologs from fission yeast and human. *Science* 1997, 277, 955-959.
- [20] Nakayama, J.; Tahara, H.; Tahara, E.; Saito, M.; Ito, K.; Nakamura, H.; Nakanishi, T.; Tahara, E.; Ide, T.; Ishikawa, F. Telomerase activation by hTERT in human normal fibroblasts and hepatocellular carcinomas. *Nat. Genet.* 1998, 18, 65-68.
- [21] Beattie, T. L.; Zhou, W.; Robinson, M. O.; Harrington, L. Reconstitution of human telomerase activity *in vitro*. *Curr. Biol.* 1998, 8, 177-180.
- [22] Takakura, M.; Kyo, S.; Kanaya, T.; Hirano, H.; Takeda, J.; Yutsudo, M.; Inoue, M. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. *Cancer Res.* 1999, 59, 551-557.
- [23] Cong, Y. S.; Wen, J.; Bacchetti, S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. *Hum. Mol. Genet.* 1999, 8, 137-142.
- [24] Horikawa, I.; Cable, P. L.; Afshari, C.; Barrett, J. C. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. *Cancer Res.* 1999, 59, 826-830.
- [25] Wick, M.; Zubov, D.; Hagen, G. Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). *Gene* 1999, 232, 97-106.
- [26] Abdul-Ghani, R.; Ohana, P.; Matouk, I.; Ayesh, S.; Ayesh, B.; Laster, M.; Bibi, O.; Giladi, H.; Molnar-Kimber, K.; Sughayer, M. A.; de, G. N.; Hochberg, A. Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. *Mol. Ther.* 2000, 2, 539-544.
- [27] Komata, T.; Koga, S.; Hirohata, S.; Takakura, M.; Germano, I. M.; Inoue, M.; Kyo, S.; Kondo, S.; Kondo, Y. A novel treatment of human malignant gliomas *in vitro* and *in vivo*: FADD gene transfer under the control of the human telomerase reverse transcriptase gene promoter. *Int. J. Oncol.* 2001, 19, 1015-1020.
- [28] Komata, T.; Kondo, Y.; Kanzawa, T.; Hirohata, S.; Koga, S.; Sumiyoshi, H.; Srinivasula, S. M.; Barna, B. P.; Germano, I. M.; Takakura, M.; Inoue, M.; Alnemri, E. S.; Shay, J. W.; Kyo, S.; Kondo, S. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. *Cancer Res.* 2001, 61, 5796-5802.
- [29] Komata, T.; Kondo, Y.; Kanzawa, T.; Ito, H.; Hirohata, S.; Koga, S.; Sumiyoshi, H.; Takakura, M.; Inoue, M.; Barna, B. P.; Germano, I. M.; Kyo, S.; Kondo, S. Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells. *Hum. Gene Ther.* 2002, 13, 1015-1025.
- [30] Gu, J.; Kagawa, S.; Takakura, M.; Kyo, S.; Inoue, M.; Roth, J. A.; Fang, B. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. *Cancer Res.* 2000, 60, 5359-5364.
- [31] Ito, H.; Kanzawa, T.; Miyoshi, T.; Hirohata, S.; Kyo, S.; Iwamaru, A.; Aoki, H.; Kondo, Y.; Kondo, S. Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status. *Hum. Gene Ther.* 2005, 16, 685-698.
- [32] Roth, J. A. Adenovirus p53 gene therapy. *Expert Opin. Biol. Ther.* 2006, 6, 55-61.
- [33] Kircheis, R.; Wagner, E. Technology evaluation: TNFerade, GenVec. *Curr. Opin. Mol. Ther.* 2003, 5, 437-447.
- [34] Wildner, O. *In situ* use of suicide genes for therapy of brain tumours. *Ann. Med.* 1999, 31, 421-429.
- [35] Hawkins, L. K.; Lemoine, N. R.; Kim, D. Oncolytic biotherapy: a novel therapeutic platform. *Lancet Oncol.* 2002, 3, 17-26.
- [36] Davis, J. J.; Fang, B. Oncolytic virotherapy for cancer treatment: challenges and solutions. *J. Gene Med.* 2005, 7, 1380-1389.
- [37] Aghi, M.; Martuza, R. L. Oncolytic viral therapies - the clinical experience. *Oncogene* 2005, 24, 7802-7816.
- [38] Takakura, M.; Kyo, S.; Kanaya, T.; Tanaka, M.; Inoue, M. Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. *Cancer Res.* 1998, 58, 1558-1561.
- [39] Hiyama, E.; Hiyama, K. Telomerase as tumor marker. *Cancer Lett.* 2003, 194, 221-233.
- [40] Hiyama, K.; Hirai, Y.; Kyoizumi, S.; Akiyama, M.; Hiyama, E.; Piatyszek, M. A.; Shay, J. W.; Ishioka, S.; Yamakido, M. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. *J. Immunol.* 1995, 155, 3711-3715.
- [41] Tahara, H.; Yasui, W.; Tahara, E.; Fujimoto, J.; Ito, K.; Tamai, K.; Nakayama, J.; Ishikawa, F.; Tahara, E.; Ide, T. Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. *Oncogene* 1999, 18, 1561-1567.
- [42] Aisner, D. L.; Wright, W. E.; Shay, J. W. Telomerase regulation: not just flipping the switch. *Curr. Opin. Genet. Dev.* 2002, 12, 80-85.
- [43] Greenberg, R. A.; O'Hagan, R. C.; Deng, H.; Xiao, Q.; Hann, S. R.; Adams, R. R.; Lichtsteiner, S.; Chin, L.; Morin, G. B.; DePinho, R. A. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. *Oncogene* 1999, 18, 1219-1226.
- [44] Wu, K. J.; Grandori, C.; Amacker, M.; Simon-Vermot, N.; Polack, A.; Lingner, J.; Dalla-Favera, R. Direct activation of TERT transcription by c-MYC. *Nat. Genet.* 1999, 21, 220-224.
- [45] Gunes, C.; Lichtsteiner, S.; Vasserot, A. P.; Englert, C. Expression of the hTERT gene is regulated at the level of transcriptional initiation and repressed by Mad1. *Cancer Res.* 2000, 60, 2116-2121.
- [46] Oh, S.; Song, Y. H.; Yim, J.; Kim, T. K. Identification of Mad as a repressor of the human telomerase (hTERT) gene. *Oncogene* 2000, 19, 1485-1490.
- [47] Kyo, S.; Takakura, M.; Taira, T.; Kanaya, T.; Itoh, H.; Yutsudo, M.; Ariga, H.; Inoue, M. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). *Nucleic Acids Res.* 2000, 28, 669-677.
- [48] Yarden, Y.; Sliwkowski, M. X. Untangling the ErbB signalling network. *Nat. Rev. Mol. Cell Biol.* 2001, 2, 127-137.
- [49] Sharrocks, A. D. The ETS-domain transcription factor family. *Nat. Rev. Mol. Cell Biol.* 2001, 2, 827-837.
- [50] Veldman, T.; Horikawa, I.; Barrett, J. C.; Schlegel, R. Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein. *J. Virol.* 2001, 75, 4467-4472.
- [51] Oh, S. T.; Kyo, S.; Laimins, L. A. Telomerase activation by human papillomavirus type 16 E6 protein: induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites. *J. Virol.* 2001, 75, 5559-5566.
- [52] Gewin, L.; Galloway, D. A. E box-dependent activation of telomerase by human papillomavirus type 16 E6 does not require induction of c-myc. *J. Virol.* 2001, 75, 7198-7201.
- [53] Oh, S.; Song, Y.; Yim, J.; Kim, T. K. The Wilms' tumor 1 tumor suppressor gene represses transcription of the human telomerase reverse transcriptase gene. *J. Biol. Chem.* 1999, 274, 37473-37478.
- [54] Fujimoto, K.; Kyo, S.; Takakura, M.; Kanaya, T.; Kitagawa, Y.; Itoh, H.; Takahashi, M.; Inoue, M. Identification and characterization of negative regulatory elements of the human telomerase catalytic subunit (hTERT) gene promoter: possible role of MZF-2 in transcriptional repression of hTERT. *Nucleic Acids Res.* 2000, 28, 2557-2562.
- [55] Crowe, D. L.; Nguyen, D. C.; Tsang, K. J.; Kyo, S. E2F-1 represses transcription of the human telomerase reverse transcriptase gene. *Nucleic Acids Res.* 2001, 29, 2789-2794.
- [56] Won, J.; Yim, J.; Kim, T. K. Opposing regulatory roles of E2F in human telomerase reverse transcriptase (hTERT) gene expression in human tumor and normal somatic cells. *FASEB J.* 2002, 16, 1943-1945.
- [57] Kyo, S.; Takakura, M.; Kanaya, T.; Zhuo, W.; Fujimoto, K.; Nishio, Y.; Orimo, A.; Inoue, M. Estrogen activates telomerase. *Cancer Res.* 1999, 59, 5917-5921.
- [58] Misi, S.; Nanni, S.; Fontemaggi, G.; Cong, Y. S.; Wen, J.; Hirte, H. W.; Piaggio, G.; Sacchi, A.; Pontecorvi, A.; Bacchetti, S.; Farsetti, A. Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells. *Mol. Cell Biol.* 2000, 20, 3764-3771.
- [59] Wang, Z.; Kyo, S.; Takakura, M.; Tanaka, M.; Yatabe, N.; Maida, Y.; Fujiwara, M.; Hayakawa, J.; Ohmichi, M.; Koike, K.; Inoue, M. Progesterone regulates human telomerase reverse transcriptase gene expression via activation of mitogen-activated protein kinase signaling pathway. *Cancer Res.* 2000, 60, 5376-5381.
- [60] Takakura, M.; Kyo, S.; Sowa, Y.; Wang, Z.; Yatabe, N.; Maida, Y.; Tanaka, M.; Inoue, M. Telomerase activation by histone deacetylase inhibitor in normal cells. *Nucleic Acids Res.* 2001, 29, 3006-3011.
- [61] He, H.; Xia, H. H.; Wang, J. D.; Gu, Q.; Lin, M. C.; Zou, B.; Lam, S. K.; Chan, A. O.; Yuen, M. F.; Kung, H. F.; Wong, B. C. Inhibition of human telomerase reverse transcriptase by nonsteroidal antiinflammatory drugs in colon carcinoma. *Cancer* 2006, 106, 1243-1249.
- [62] Ikeda, N.; Uemura, H.; Ishiguro, H.; Hori, M.; Hosaka, M.; Kyo, S.; Miyamoto, K.; Takeda, E.; Kubota, Y. Combination treatment with 1alpha,25-dihydroxyvitamin D3 and 9-cis-retinoic acid directly inhibits human telomerase reverse transcriptase transcription in prostate cancer cells. *Mol. Cancer Ther.* 2003, 2, 739-746.
- [63] Pendino, F.; Dudognon, C.; Delhommeau, F.; Sahraoui, T.; Flexor, M.; naceur-Grisicelli, A.; Lanotte, M.; Segal-Bendirdjian, E. Retinoic acid receptor alpha and retinoid-X receptor-specific agonists synergistically target telomerase expression and induce tumor cell death. *Oncogene* 2003, 22, 9142-9150.
- [64] Rodriguez, R.; Schuur, E. R.; Lim, H. Y.; Henderson, G. A.; Simons, J. W.; Henderson, D. R. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. *Cancer Res.* 1997, 57, 2559-2563.
- [65] Kurihara, T.; Brough, D. E.; Kovedli, I.; Kufe, D. W. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. *J. Clin. Invest.* 2000, 106, 763-771.
- [66] Matsubara, S.; Wada, Y.; Gardner, T. A.; Egawa, M.; Park, M. S.; Hsieh, C. L.; Zhou, H. E.; Kao, C.; Kamidono, S.; Gillenwater, J. Y.; Chung, L. W. A conditional replication-competent adenoviral vector, Ad-OC-E1a,

- to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. *Cancer Res.* 2001, *61*, 6012-6019.
- [67] Peng, X. Y.; Won, J. H.; Rutherford, T.; Fujii, T.; Zelterman, D.; Pizzomo, G.; Sapi, E.; Leavitt, J.; Kacinski, B.; Crystal, R.; Schwartz, P.; Deisseroth, A. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. *Cancer Res.* 2001, *61*, 4405-4413.
- [68] Adachi, Y.; Reynolds, P. N.; Yamamoto, M.; Wang, M.; Takayama, K.; Matsubara, S.; Muramatsu, T.; Curiel, D. T. A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. *Cancer Res.* 2001, *61*, 7882-7888.
- [69] Tsukuda, K.; Wiewrodt, R.; Molnar-Kimber, K.; Jovanovic, V. P.; Amin, K. M. An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell. *Cancer Res.* 2002, *62*, 3438-3447.
- [70] Wirth, T.; Zender, L.; Schulte, B.; Mundt, B.; Plentz, R.; Rudolph, K. L.; Manns, M.; Kubicka, S.; Kuhnle, F. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. *Cancer Res.* 2003, *63*, 3181-3188.
- [71] Lanson, N. A., Jr.; Friedlander, P. L.; Schwarzenberger, P.; Kolls, J. K.; Wang, G. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. *Cancer Res.* 2003, *63*, 7936-7941.
- [72] Irving, J.; Wang, Z.; Powell, S.; O'Sullivan, C.; Mok, M.; Murphy, B.; Cardoza, L.; Lebkowski, J. S.; Majumdar, A. S. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. *Cancer Gene Ther.* 2004, *11*, 174-185.
- [73] Li, Y.; Yu, D. C.; Chen, Y.; Amin, P.; Zhang, H.; Nguyen, N.; Henderson, D. R. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. *Cancer Res.* 2001, *61*, 6428-6436.
- [74] Kawashima, T.; Kagawa, S.; Kobayashi, N.; Shirakiya, Y.; Umeoka, T.; Teraishi, F.; Taki, M.; Kyo, S.; Tanaka, N.; Fujiwara, T. Telomerase-specific replication-selective virotherapy for human cancer. *Clin. Cancer Res.* 2004, *10*, 285-292.
- [75] Taki, M.; Kagawa, S.; Nishizaki, M.; Mizuguchi, H.; Hayakawa, T.; Kyo, S.; Nagai, K.; Urata, Y.; Tanaka, N.; Fujiwara, T. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 (Telomelysin-RGD). *Oncogene* 2005, *24*, 3130-3140.
- [76] Watanabe, T.; Hioki, M.; Fujiwara, T.; Nishizaki, M.; Kagawa, S.; Taki, M.; Kishimoto, H.; Endo, Y.; Urata, Y.; Tanaka, N.; Fujiwara, T. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. *Exp. Cell Res.* 2006, *312*, 256-265.
- [77] Fujiwara, T.; Kagawa, S.; Kishimoto, H.; Endo, Y.; Hioki, M.; Ikeda, Y.; Sakai, R.; Urata, Y.; Tanaka, N.; Fujiwara, T. Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: Preclinical evaluation of chemovirotherapy. *Int. J. Cancer* 2006, *119*, 432-440.
- [78] Ito, H.; Aoki, H.; Kuhnle, F.; Kondo, Y.; Kubicka, S.; Wirth, T.; Iwado, E.; Iwamaru, A.; Fujiwara, K.; Hess, K. R.; Lang, F. F.; Swaya, R.; Kondo, S. Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. *J. Natl. Cancer Inst.* 2006, *98*, 625-636.
- [79] Kabeya, Y.; Mizushima, N.; Ueno, T.; Yamamoto, A.; Kirisako, T.; Noda, T.; Kominami, E.; Ohsumi, Y.; Yoshimori, T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. *EMBO J.* 2000, *19*, 5720-5728.
- [80] Khuri, F. R.; Nemunaitis, J.; Ganly, I.; Arseneau, J.; Tannock, I. F.; Romel, L.; Gore, M.; Ironside, J.; MacDougall, R. H.; Heise, C.; Randlev, B.; Gillenwater, A. M.; Brusco, P.; Kaye, S. B.; Hong, W. K.; Kim, D. H. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. *Nat. Med.* 2000, *6*, 879-885.
- [81] Reid, T.; Galanis, E.; Abbruzzese, J.; Sze, D.; Wein, L. M.; Andrews, J.; Randlev, B.; Heise, C.; Upprichard, M.; Hatfield, M.; Rome, L.; Rubin, J.; Kim, D. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. *Cancer Res.* 2002, *62*, 6070-6079.
- [82] Hecht, J. R.; Bedford, R.; Abbruzzese, J. L.; Lahoti, S.; Reid, T. R.; Soetikno, R. M.; Kim, D. H.; Freeman, S. M. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. *Clin. Cancer Res.* 2003, *9*, 555-561.
- [83] Galanis, E.; Okuno, S. H.; Nascimento, A. G.; Lewis, B. D.; Lee, R. A.; Oliveira, A. M.; Sloan, J. A.; Atherton, P.; Edmonson, J. H.; Erlichman, C.; Randlev, B.; Wang, Q.; Freeman, S.; Rubin, J. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. *Gene Ther.* 2005, *12*, 437-445.
- [84] Nemunaitis, J.; Ganly, I.; Khuri, F.; Arseneau, J.; Kuhn, J.; McCarty, T.; Landers, S.; Maples, P.; Romel, L.; Randlev, B.; Reid, T.; Kaye, S.; Kim, D. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. *Cancer Res.* 2000, *60*, 6359-6366.
- [85] Jacobs, C.; Lyman, G.; Velez-Garcia, E.; Sridhar, K. S.; Knight, W.; Hochster, H.; Goodnough, L. T.; Mortimer, J. E.; Einhorn, L. H.; Schacter, L. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. *J. Clin. Oncol.* 1992, *10*, 257-263.
- [86] Vokes, E. E. Chemotherapy and integrated treatment approaches in head and neck cancer. *Curr. Opin. Oncol.* 1991, *3*, 529-534.
- [87] Shaked, Y.; Emmenegger, U.; Francia, G.; Chen, L.; Lee, C. R.; Man, S.; Paraghamian, A.; Ben-David, Y.; Kerbel, R. S. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. *Cancer Res.* 2005, *65*, 7045-7051.
- [88] Kitazono, M.; Goldsmith, M. E.; Aikou, T.; Bates, S.; Fojo, T. Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228. *Cancer Res.* 2001, *61*, 6328-6330.
- [89] Goldsmith, M. E.; Kitazono, M.; Fok, P.; Aikou, T.; Bates, S.; Fojo, T. The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cells. *Clin. Cancer Res.* 2003, *9*, 5394-5401.
- [90] Pong, R. C.; Lai, Y. J.; Chen, H.; Okegawa, T.; Frenkel, E.; Sagalowsky, A.; Hsieh, J. T. Epigenetic regulation of coxsackie and adenovirus receptor (CAR) gene promoter in urogenital cancer cells. *Cancer Res.* 2003, *63*, 8680-8686.
- [91] Hemminki, A.; Kanerva, A.; Liu, B.; Wang, M.; Alvarez, R. D.; Siegal, G. P.; Curiel, D. T. Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. *Cancer Res.* 2003, *63*, 847-853.
- [92] Fujiwara, T.; Tanaka, N.; Kanazawa, S.; Ohtani, S.; Saijo, Y.; Nukiwa, T.; Yoshimura, K.; Sato, T.; Eto, Y.; Chada, S.; Nakamura, H.; Kato, H. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. *J. Clin. Oncol.* 2006, *24*, 1689-1699.
- [93] DeWeese, T. L.; van der, P. H.; Li, S.; Mikhak, B.; Drew, R.; Goemann, M.; Hamper, U.; DeJong, R.; Detorie, N.; Rodriguez, R.; Haulk, T.; DeMarzo, A. M.; Piantadosi, S.; Yu, D. C.; Chen, Y.; Henderson, D. R.; Carducci, M. A.; Nelson, W. G.; Simons, J. W. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. *Cancer Res.* 2001, *61*, 7464-7472.
- [94] Small, E. J.; Carducci, M. A.; Burke, J. M.; Rodriguez, R.; Fong, L.; van, U. L.; Yu, D. C.; Aimi, J.; Ando, D.; Working, P.; Kim, D.; Wilding, G. A Phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. *Mol. Ther.* 2006, *14*, 107-117.
- [95] Tearney, G. J.; Brezinski, M. E.; Bouma, B. E.; Boppart, S. A.; Pitris, C.; Southern, J. F.; Fujimoto, J. G. *In vivo* endoscopic optical biopsy with optical coherence tomography. *Science* 1997, *276*, 2037-2039.
- [96] Kelloff, G. J.; Hoffman, J. M.; Johnson, B.; Scher, H. I.; Siegel, B. A.; Cheng, E. Y.; Cheson, B. D.; O'shaughnessy, J.; Guyton, K. Z.; Mankoff, D. A.; Shankar, W.; Larson, S. M.; Sigman, C. C.; Schilsky, R. L.; Sullivan, D. C. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. *Clin. Cancer Res.* 2005, *11*, 2785-2808.
- [97] Hoffman, R. M. The multiple uses of fluorescent proteins to visualize cancer *in vivo*. *Nat. Rev. Cancer* 2005, *5*, 796-806.
- [98] Umeoka, T.; Mizushima, T.; Kagawa, S.; Teraishi, F.; Taki, M.; Nishizaki, M.; Kyo, S.; Nagai, K.; Urata, Y.; Tanaka, N.; Fujiwara, T. Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene. *Cancer Res.* 2004, *64*, 6259-6265.
- [99] Kishimoto, H.; Kojima, T.; Watanabe, Y.; Kagawa, S.; Fujiwara, T.; Uno, F.; Teraishi, F.; Kyo, S.; Mizuguchi, H.; Hasimoto, Y.; Urata, Y.; Tanaka, N.; Fujiwara, T. *In vivo* imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. *Nat. Med.* 2006, *12*, 1213-1219.
- [100] Okada, N.; Tsukada, Y.; Nakagawa, S.; Mizuguchi, H.; Mori, K.; Saito, T.; Fujita, T.; Yamamoto, A.; Hayakawa, T.; Mayumi, T. Efficient gene delivery into dendritic cells by fiber-mutant adenovirus vectors. *Biochem. Biophys. Res. Commun.* 2001, *282*, 173-179.

ORIGINAL ARTICLE

Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation

Y Endo^{1,2}, R Sakai^{1,2}, M Ouchi³, H Onimatsu³, M Hioki^{1,2}, S Kagawa^{1,2}, F Uno^{1,2}, Y Watanabe³, Y Urata³, N Tanaka¹ and T Fujiwara^{1,2}

¹Division of Surgical Oncology, Department of Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; ²Center for Gene and Cell Therapy, Okayama University Hospital, Okayama, Japan and ³Oncolys BioPharma Inc., Tokyo, Japan

Dendritic cells (DCs) are the most potent antigen-presenting cells and acquire cellular antigens and danger signals from dying cells to initiate antitumor immune responses via direct cell-to-cell interaction and cytokine production. The optimal forms of tumor cell death for priming DCs for the release of danger signals are not fully understood. OBP-301 (Telomelysin) is a telomerase-specific replication-competent adenovirus that induces selective E1 expression and exclusively kills human cancer cells. Here, we show that OBP-301 replication produced the endogenous danger signaling molecule, uric acid, in infected human tumor cells, which in turn stimulated DCs to produce interferon- γ (IFN- γ) and interleukin 12 (IL-12). Subsequently, IFN- γ release upregulated the endogenous expression of the proteasome activator PA28 in tumor cells and resulted in the induction of cytotoxic T-lymphocytes. Our data suggest that virus-mediated oncolysis might be the effective stimulus for immature DCs to induce specific activity against human cancer cells. *Oncogene* advance online publication, 5 November 2007; doi:10.1038/sj.onc.1210884

Keywords: adenovirus; telomerase; dendritic cell; uric acid; danger signal

Introduction

Dendritic cells (DCs) are the most important professional antigen-presenting cells and play a critical role in the induction of primary immune responses against tumor-associated antigens. Mature DCs express high levels of major histocompatibility complex (MHC) class I, II and co-stimulatory molecules such as CD80 and CD86, and secrete T-helper type-1 (Th1) cytokines such as interleukin (IL)-12 and interferon (IFN)- γ . DCs acquire

endogenous maturation stimuli from dying cells as a danger signal when they capture cellular antigens. Lack of danger signals delays maturation of DCs and causes active suppression of DCs stimulatory capacity, leading to the induction of T-cell tolerance (Steinman *et al.*, 2000). Shi *et al.* (2003) have previously identified uric acid as a novel endogenous warning molecule capable of alerting the immune system within cell lysates. The uric acid activates DCs following relocation from the inside to the outside of injured cells and converts immunity from non-protective to protective. In fact, it has been reported that uric acid levels are elevated in tumors undergoing immune rejection and that the inhibition of uric acid production delays tumor regression (Hu *et al.*, 2004).

Viruses have evolved to infect, replicate in and kill human cells through diverse mechanisms such as direct cell death machinery and fairly brisk immune responses. We reported previously that telomerase-specific replication-competent adenovirus (Telomelysin, OBP-301), in which the human telomerase reverse transcriptase (hTERT) promoter element drives the expression of *E1A* and *E1B* genes linked with an internal ribosome entry site (IRES), induced selective E1 expression and efficiently killed human cancer cells, but not normal human fibroblasts (Kawashima *et al.*, 2004; Umeoka *et al.*, 2004; Taki *et al.*, 2005; Watanabe *et al.*, 2006). Although the precise molecular mechanism of OBP-301-induced cell death is still unclear, the process of oncolysis is morphologically distinct from apoptosis and necrosis. These findings led us to examine whether tumor cells killed by OBP-301 infection could stimulate DCs, thus enhancing the immune response.

In the present study, we compared three types of tumor preparations as a source of cell-derived antigen for the priming of DCs: virus-induced oncolysis, chemotherapeutic drug-induced apoptosis and necrosis by freeze/thaw. We also explored the cytokine signature and activating property of these cells for antitumor immune response against human cancer cells.

Results

We first examined whether OBP-301 infection affects the viability of human cancer cells using the XTT assay.

Correspondence: Dr T Fujiwara, Center for Gene and Cell Therapy, Okayama University Hospital, 2-5-1 Shikata-cho, Okayama 700-8558, Japan.

E-mail: toshi_f@md.okayama-u.ac.jp

Received 30 July 2007; revised 14 September 2007; accepted 17 September 2007

OBP-301 infection induced death of human cancer cell lines (H1299 human lung cancer and SW620 human colorectal cancer cells) in a dose-dependent manner (Figure 1). Although autophagy, or type II programmed cell death, partially involved in the cell death machinery triggered by OBP-301 infection, oncolytic cells are distinct from apoptotic cells (Supplementary Figure 1).

We next examined whether OBP-301 infection modulated intracellular concentrations of uric acid that might act as a danger signal in tumor cells. Uric acid levels increased in H1299 cells following OBP-301 infection in a time-dependent fashion, although docetaxel slightly upregulated the uric acid concentration 72 h after treatment (Figure 2a). Thus, tumor cells undergoing oncolysis can produce significantly greater amounts of uric acid when compared with apoptotic tumor cells. The uric acid elevation pattern of OBP-301-infected cells almost paralleled that of cells infected with Onyx-015, an E1B 55 kDa-deleted adenovirus engineered to selectively replicate in and lyse p53-deficient cancer cells, and wild-type adenovirus type 5 (Figure 2b), indicating a general effect of adenovirus infection in the regulation of intracellular uric acid levels.

Uric acid is produced during the catabolism of purines and is the end product of this process. Adenoviral replication facilitates the purine catabolism to stimulate the synthesis of progeny DNA, which in turn may increase intracellular uric acid levels by the purine degradation process. In fact, OBP-301 infection significantly increased the amount of uric acid in the cells, whereas replication-deficient dl312 infection had no apparent effect on the levels of uric acid. OBP-301-induced elevation of uric acid levels could be inhibited in the presence of cidofovir (CDV), an acyclic nucleoside phosphonate having potent broad-spectrum anti-DNA virus activity (Figure 2c). CDV has been approved for the treatment of many types of viruses including cytomegalovirus and adenovirus (Lenaerts and Naesens,

2006). We confirmed that CDV at 100 μ M could significantly inhibited replication of OBP-301 in H1299 cells by the real-time quantitative PCR analysis (Supplementary Figure 2). Moreover, as OBP-301 replication was attenuated in telomerase-negative cells, the levels of uric acid could not be altered in normal human lung fibroblasts (NHLF) after OBP-301 infection (Figure 2d). These results suggest that viral replication is required to produce uric acid in infected cells.

Xanthine oxidoreductase (XOR) is a member of the molybdoflavoenzyme family that catalyses the formation of uric acid from xanthine and hypoxanthine (Glantzounis *et al.*, 2005). A strand-specific reverse transcriptase PCR assay demonstrated that XOR mRNA expression gradually decreased in OBP-301-infected cells presumably due to the negative feedback of increased uric acid levels, whereas docetaxel-treated cells yielded consistent bands of the XOR transcripts (Figure 2e). Thus, adenoviral replication could directly stimulate the catalytic DNA turnover, which enables cells to produce more uric acid.

We then examined the ability of OBP-301-infected cells to stimulate immature DCs *in vitro*. DCs generated from HLA-A24⁺ healthy volunteers were co-cultured with HLA-matched H1299 cells (HLA-A32/A24) treated with OBP-301 or docetaxel for 72 h, or freeze thawed. The production of Th1 cytokines such as IFN- γ and IL-12 in the supernatants was then explored by enzyme-linked immunosorbent assay (ELISA) analysis 48 h after the co-culture. DCs incubated with OBP-301-infected cells secreted large amounts of IFN- γ and IL-12, whereas stimulation with docetaxel-treated apoptotic cells induced their secretion at low levels (Figure 3a). The level of cytokine production from DCs incubated with freeze-thawed necrotic cells was similar to that of untreated immature DCs. Moreover, we confirmed that addition of OBP-301 alone without target tumor cells did not affect the cytokine secretion of DCs into the supernatant, indicating that infection of OBP-301 itself had no apparent effect on DCs. Thus, DCs stimulated with oncolytic tumor cells preferentially secrete high-level Th1 cytokines. Flow cytometry demonstrated that the increase in the expression of CD83, which is expressed on mature DCs, was slightly higher on DCs incubated with oncolytic cells than those with apoptotic or necrotic cells, indicating that oncolytic tumor cells seems to have a positive influence on DC maturation (Supplementary Figure 3).

In the next step, we investigated the effects of oncolytic tumor cells on T-cell activation in the presence of DCs. H1299 cells were infected with OBP-301 over 72 h, and then co-incubated with HLA-matched HLA-A24⁺ peripheral blood mononuclear cells (PBMCs) for another 48 h in mixed lymphocyte tumor culture (MLTC). In other tests, H1299 cells were exposed to docetaxel for 72 h or freeze thawed, and then co-cultured with PBMCs. We examined the secretion of IFN- γ and IL-12 into the supernatants after MLTC for 7 days. Stimulation with OBP-301-infected cells induced the secretion of high levels of IFN- γ and IL-12 into MLTC supernatants, which was significantly higher




Figure 1 *In vitro* cytopathic effects of OBP-301 on human cancer cells. H1299 human non-small cell lung cancer (a) and SW620 human colorectal cancer cells (b) were infected with OBP-301 at indicated multiplicity of infection (MOI) values, and surviving cells were quantitated over 7 days by XTT assay. The cell viability of mock-treated cells on day 1 was considered 1.0, and the relative cell viability was calculated. Each data represent the mean \pm standard deviation (s.d.) of triplicate experiments.




Figure 2 (a) Uric acid concentrations in H1299 cells treated with OBP-301 or docetaxel. H1299 cells were infected with 1.0 MOI of OBP-301 or treated with 10 nM of docetaxel for indicated time periods, and uric acid concentrations were determined enzymatically in the cell homogenates. Single asterisk indicates $P < 0.01$, significantly different from docetaxel-treated cells. (b) Uric acid levels in H1299 cells treated with OBP-301, Onyx-015 or wild-type adenovirus. H1299 cells were harvested at indicated time points over 72 h after infection with 10 MOI of viruses, and subjected to the measurement of uric acid concentrations. The levels of uric acid concentration are defined as the fold-increase for each sample relative to that of mock-treated cells (mock equals 1). Single asterisk indicates $P < 0.01$, significantly different from mock-treated cells. (c) Uric acid concentrations in H1299 cells infected with 1.0 MOI of OBP-301 or replication-deficient dl312 adenovirus were measured 24 h after infection. Uric acid production was also assessed in H1299 cells infected with 1.0 MOI of OBP-301 in the presence of 100 μM of anti-virus agent cidofovir (CDV). H1299 cells treated with 100 μM of CDV were subjected to the assay as a control. All uric acid levels are normalized to that of mock-treated cells (mock equals 1). (d) Uric acid levels in NHLF infected with OBP-301. NHLF cells were infected with 1.0 MOI of OBP-301 for indicated time periods, and uric acid concentrations were measured. The uric acid levels are normalized to that of mock-treated cells. (e) Detection of xanthine oxidoreductase (XOR) mRNA expression in OBP-301-infected H1299 cells by RT-PCR analysis. Cells were infected with 1.0 MOI of OBP-301 or treated with 10 nM of docetaxel, and then collected at the indicated time points. First-strand DNA generated from RNA was amplified using either the primers specific for XOR sequence or the primers that recognize β -actin sequences as an internal control.

than that with docetaxel-treated or freeze-thawed H1299 cells (Figure 3b). Thus, oncolytic tumor cells can accelerate the cleavage of tumor antigen peptides that can be associated with MHC class I molecules via IFN- γ secretion by immune cells.

Stimulation of cells with IFN- γ is known to induce the expression of PA28, a proteasome activator that accelerates the *in vitro* processing of MHC class I ligands from their polypeptide precursors (Sun *et al.*, 2002). We investigated whether PA28 expression was upregulated in H1299 cells by adding the supernatants of co-cultures of PBMCs and OBP-301-infected H1299 cells. Western blot analysis for PA28 demonstrated that, following heat inactivation of residual OBP-301, MLTC supernatants with oncolytic tumor cells induced a strong endogenous PA28 expression in H1299 cells. In contrast, exposure to the supernatants of PBMCs alone, PBMCs with untreated H1299 cells, and PBMCs with oncolytic

tumor cells without heat inactivation resulted in no apparent changes in the expression levels of PA28 (Figure 4).

Finally, the cytotoxic T-lymphocyte (CTL) response against human cancer cells was assessed by a standard 6-h ^{51}Cr release assay after a 7-day MLTC using various forms of H1299 cells. The lytic activity of CTLs induced by apoptotic or necrotic H1299 cells was comparable with that of human lymphokine-activated killer (LAK) cells; CTLs stimulated with oncolytic H1299 cells, however, more efficiently killed target H1299 cells (Figure 5). In contrast, LAK cells effectively lysed SW620 cells, whereas these cells were minimally killed by CTLs stimulated with apoptotic, necrotic or oncolytic H1299 cells. Furthermore, HLA-unmatched, HLA-A26/A30 $^{+}$ A549 human lung cancer cells were not sensitive to oncolytic tumor cell-induced cytotoxicity (data not shown), suggesting that effector cells stimulated with




Figure 3 (a) Secretion of Th1-type cytokines by oncolytic, apoptotic or necrotic tumor cells. H1299 cells were treated with 1.0 MOI of OBP-301 or 50 nM of docetaxel for 72 h, or freeze thawed, and then co-cultured with immature dendritic cells (DCs) obtained from monocytes for additional 48 h. The culture supernatants were harvested and tested by ELISA for interferon (IFN)- γ (left) and interleukin (IL)-12 (right) concentrations. As a control, the supernatants of immature DCs alone or with OBP-301 at an MOI of 1.0 were also examined. Data are mean \pm s.d. of triplicate experiments. Single asterisk indicates $P < 0.01$, significantly different from other groups. (b) Tumor-specific CTL induction in MLTC with oncolytic, apoptotic or necrotic tumor cells. IFN- γ (left) and IL-12 (right) concentrations in the supernatants of MLTC analysed by ELISA. H1299 cells were treated with 1.0 MOI of OBP-301 or 50 nM of docetaxel for 72 h, or freeze thawed, and then co-cultured with PBMCs obtained from HLA-A24⁺ healthy volunteers for 48 h in MLTC. Data are mean \pm s.d. of triplicate experiments. Single asterisk indicates $P < 0.01$, significantly different from other groups.

OBP-301-infected tumor cells exhibit MHC class I-restricted reactivity.

Discussion

In the present study, our goal was to determine whether oncolytic virus is effective not only as a direct cytotoxic drug but also as an immunostimulatory agent that could induce specific CTL for the remaining antigen-bearing tumor cells. Several groups have debated whether necrotic or apoptotic cells can stimulate DCs to cross-present cell-derived peptides, with subsequent enhancement of tumor immunogenicity. Furthermore, it has been reported recently that the immunogenicity of tumors is not regulated by signals associated with apoptotic or necrotic cell death, but is an intrinsic feature of the tumor itself (Bartholomae *et al.*, 2004). Our data indicate that viral oncolysis could efficiently load tumor antigen on DCs, and then generate CTL response as judged from

the production of cytokines. Moreover, the CTL activity against untreated tumor cells suggests that CTLs are specific to tumor antigens, but not to adenovirus proteins.

DCs are known to ingest dying tumor cells and initiate tumor-specific responses when associated with appropriate danger signals, which are endogenous activation signals liberated by dying cells. Recent studies have shown that some intrinsic biochemical factors, such as uric acid, bradykinin and heat shock protein (HSP110) act as danger signals through their interaction with DCs, and influence the subsequent immune response (Aliberti *et al.*, 2003; Shi *et al.*, 2003; Manjili *et al.*, 2005). Large amounts of uric acid can be produced following tissue injury *in vivo*, and activate the immune response against injured cells and dying tissues. We found that OBP-301 infection increased intracellular uric acid levels in human tumor cells compared with apoptosis- or necrosis-inducing stimuli, suggesting that viral replication itself can enhance tumorigenicity.




Figure 4 (a) Western blot analysis of PA28 in H1299 cells exposed to the supernatants of MLTC. peripheral blood mononuclear cells (PBMCs) were incubated with mock, untreated H1299 cells or H1299 cells treated with 10 MOI of OBP-301 for 72 h in MLTC, and the supernatants were harvested 48 h after the co-culture. H1299 cells were further incubated with the supernatants for 72 h with or without heat inactivation of residual virus (56°C, 10 min). H1299 cells were also incubated with 5 ng ml⁻¹ of interferon (IFN)- γ with or without heating for 72 h. Equivalent amounts of protein obtained from whole cell lysates were loaded in each lane, probed with anti-PA28 antibody and then visualized by using an ECL detection system. Equal loading of samples was confirmed by stripping each blot and reprobing with anti-actin antiserum. (b) PA28 protein expression was quantified by densitometric scanning using NIH Image software and normalization by dividing the actin signal.




Figure 5 Cytolytic reactivity against H1299 (a) and SW620 (b) human cancer cells was assessed after 7-day mixed lymphocyte tumor culture (MLTC) with oncolytic, apoptotic or necrotic H1299 cells treated the same as above by 6-h standard ⁵¹Cr-release assay. Lymphokine-activated killer (LAK) cells were generated from peripheral blood mononuclear cells (PBMCs) in the presence of interleukin (IL)-2 (100 U ml⁻¹) for 3 days. The CTLs were compared with LAK cells and untreated PBMCs, which served as positive and negative controls, respectively. Data represent the mean \pm s.d. of three wells at four different effector-to-target (E/T) ratios.

Viral oncolysis increases the immunogenicity of tumor cells presumably by the release of proinflammatory cytokines (Lindenmann and Klein, 1967). We showed that OBP-301-infected oncolytic tumor cells

efficiently stimulated immature DCs to produce greater amounts of IFN- γ and IL-12 than apoptotic and necrotic cells, and that such stimulation led to DC maturation. Viral infection itself has been reported to activate DCs to secrete pro- or anti-inflammatory cytokines, which can drive DCs to undergo the maturation process (Ho et al., 2001); the observation that OBP-301 alone had no effect on cytokine production by DCs, however, indicates that OBP-301 itself may be less infective or stimulatory to DCs. The result is consistent with our finding that OBP-301 attenuated replication as well as cytotoxicity in human normal cells.

It will be of interest to more mechanistically define why viral oncolysis efficiently induces CTL activity against tumor cells. We hypothesized that viral replication itself or the released cytokines by immune cells positively influences tumor cell immunogenicity. The IFN- γ -inducible proteasome modulator complex PA28 participates in the generation of antigenic peptides required for MHC class I antigen presentation (Sijts et al., 2002). As expected, the supernatants of MLTC with OBP-301-infected tumor cells, in which IFN- γ secretion was detected, induced a strong expression of endogenous PA28. Thus, oncolytic tumor cells can accelerate the cleavage of tumor antigen peptides that can be associated with MHC class I molecules via IFN- γ secretion by immune cells. In fact, it has been reported that restoration of PA28 expression in PA28-deficient melanoma cells rescues the melanoma antigen epitope presentation (Sun et al., 2002); our preliminary experiments however demonstrated that human tumor cells transfected with PA28 α expression vector were less sensitive to tumor-specific CTLs (data not shown). These observations suggest that antigen peptide production alone does not seem sufficient to enhance tumor immunogenicity.

In conclusion, we provide for the first time evidence that oncolytic virus replication induces tumor-specific immune responses by stimulating uric acid production as a danger signal as well as accelerating tumor antigen cleavage by IFN- γ -inducible PA28 expression. Since the induction of systemic immunity has rarely been observed in clinical trials with other conditionally replication-competent viruses, more *in vivo* experiments are clearly required to support the induction of antitumor immunity by OBP-301 treatment. Our data, however, suggest that the antitumor effect of OBP-301 might be potentially both direct and indirect as well as systemic rather than local.

Materials and methods

Cell lines and reagents

The human non-small lung cancer cell lines H1299 (HLA-A32/A24) and the human colorectal carcinoma cell lines SW620 (HLA-A02/A24) were maintained *in vitro* in RPMI 1640 supplemented with 10% fetal calf serum, 100 U ml⁻¹ penicillin and 100 mg ml⁻¹ streptomycin. Recombinant human cytokines granulocyte/macrophage colony-stimulating factor (GM-CSF), IL-4, TNF- α and IL-7 were purchased from Genzyme

Techne (Minneapolis, MN, USA), IFN- γ from Peptrotech (Rocky Hill, NJ, USA) and IL-2 from Roche (Mannheim, Germany). [^{51}Cr] sodium chromate was obtained from NEN Life Science Products (Boston, MA, USA). Docetaxel (taxotere) was kindly provided by Aventis Pharma (Tokyo, Japan).

Adenovirus

The recombinant replication-selective, tumor-specific adenovirus vector OBP-301 (Telomelysin), in which the hTERT promoter element drives the expression of *E1A* and *E1B* genes linked with an IRES, was constructed and characterized previously (Kawashima et al., 2004; Umeoka et al., 2004; Taki et al., 2005; Watanabe et al., 2006). Onyx-015 (dl1520) is an E1B 55 kDa-deleted adenovirus engineered to selectively replicate in and lyse p53-deficient cancer cells, and kindly provided by Dr Frank McCormick (UCSF Comprehensive Cancer Center and Cancer Research Institute). The E1A-deleted adenovirus vector lacking a cDNA insert (dl312) was also used as a control vector. The viruses were purified by CsCl₂ step gradient ultracentrifugation followed by CsCl₂ linear gradient ultracentrifugation.

Cell viability assay

XTT assay was performed to measure cell viability. Briefly, cells were plated on 96-well plates at 5×10^3 per well 24 h before treatment and then infected with OBP-301 or exposed to docetaxel. Cell viability was determined at the times indicated by using a Cell Proliferation Kit II (Roche Molecular Biochemicals) according to the protocol provided by the manufacturer.

Reverse transcription (RT)-PCR

Total RNA was isolated from mock-, OBP-301- and docetaxel-treated cells using RNazol (Cinna/BioTex, Friendswood, TX, USA) in a single-step phenol-extraction method and used as templates. Reverse transcription was performed at 22 °C for 10 min and then 42 °C for 20 min using 1.0 μg of RNA per reaction to ensure that the amount of amplified DNA was proportional to that of specific mRNA in the original sample. PCR was performed with specific primers in volumes of 50- μl according to the protocol provided by the manufacturer (PCR kit; Perkin-Elmer/Cetus, Norwalk, CT, USA). The specific primers used for XOR were 5'-GCG AAG GAT AAG GTT ACT TGT-3' (forward) and 5'-CTC CAG GTA GAA GTG CTC TTG-3' (reverse); and for β -actin were 5'-ATG GTG GGA ATG GGT CAG AAG-3' (forward) and 5'-GCA GCT CAT TGT AGA AGG-3' (reverse). The reaction conditions were denaturing at 94 °C for 2 min followed by 30 cycles consisting of denaturing at 94 °C (30 s), annealing at 65 °C (15 s) and extension at 72 °C (10 s) using a thermal cycler (Perkin-Elmer, Foster City, CA, USA). The reactions were completed by a final 2-min extension at 72 °C. The PCR products were resolved on 1% agarose gels and visualized by SYBR Gold Nucleic Acid Gel Stain (Molecular Probes Inc., Eugene, OR, USA).

Preparation of tumor cells

For induction of oncolysis, tumor cells were infected with OBP-301 at a multiplicity of infection (MOI) of 1–10, and then collected 24–72 h after infection. Apoptotic tumor cells were obtained after 24–72-h exposure to 50–100 nM of docetaxel. For induction of necrosis, tumor cells suspended in phosphate-buffered saline (PBS) were subjected to rapid four freeze/thaw cycles using a 60 °C water bath and liquid nitrogen.

Measurement of uric acid concentration

Cultured cells were harvested after treatment and rinsed three times with PBS. These cells were resuspended in lysis buffer at a density of 200×10^6 cells per 100 μl . The buffer contained 10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 50 mM NaF, 1 mM ethylenediaminetetraacetic acid (EDTA), 0.5 mM Na₃VO₄, 10% glycerol, 0.5% NP-40 and 0.1 mM phenylmethylsulfonyl fluoride (PMSF). After 10-s homogenization, the resulting extracts were kept on ice for 30 min and then were centrifuged for 15 min at 2000 g. The supernatants from treated tumor cells were assayed for uric acid using Uric Acid C test (Wako, Osaka, Japan).

Preparation of DCs

Peripheral blood samples were obtained from normal HLA-A24 positive healthy volunteers and PBMC were isolated by sedimentation over Ficoll-Hypaque. They were subsequently allowed to adhere in culture flasks for 1 h at 37 °C at a density of 4.0×10^7 cells per plate. Non-adherent cells in the plate were removed and the remaining (adherent) cells were cultured for 7 days in AIM-V (Gibco, Rockville, MD, USA) containing 2% heated-inactivated autologous serum supplemented with GM-CSF (50 ng ml⁻¹) and IL-4 (50 ng ml⁻¹).

Cytokine production assay

DCs were co-cultured with treated tumor cells at a ratio of 3:1 (DC/tumor cell) in a culture medium containing GM-CSF (50 ng ml⁻¹) and IL-4 (50 ng ml⁻¹). After 24-h incubation, the supernatant was collected and stored at -80 °C until the assay. The concentrations of IFN- γ and IL-12 (p40 and p70) were measured with appropriate ELISA kits (BioSource, Camarillo, CA, USA).

MLTC and CTL assay

PBMCs were co-cultured with treated tumor cells at a ratio of 20:1 in the presence of IL-2 (Roche) (10 U ml⁻¹) and IL-7 (Genzyme Techne) (5 ng ml⁻¹) for 7 days. Cultured cells were then used as effector cells in a standard 4 h-⁵¹Cr release assay and the percentage of lysed cells was calculated. Percent specific lysis = ((experimental cpm - spontaneous cpm) / (maximal cpm - spontaneous cpm) \times 100). Supernatants from MLTC performed as above were also assayed for IFN- γ and IL-12 by ELISA assays (BioSource).

Western blot analysis

The primary antibodies against proteasome activator PA28 (ZMD353; Invitrogen, Carlsbad, CA, USA), actin (AC-40; Sigma Chemical Co., St. Louis, MO, USA) and peroxidase-linked secondary antibody (Amersham, Arlington Heights, IL, USA) were used. Cells were washed twice in cold PBS and collected, then lysed in lysis buffer (10 mM Tris (pH 7.5), 150 mM NaCl, 50 mM NaF, 1 mM EDTA, 10% glycerol and 0.5% NP40) containing proteinase inhibitors (0.1 mM PMSF and 0.5 mM Na₃VO₄). After 20 min on ice, the lysates were spun at 14 000 rpm in a microcentrifuge at 4 °C for 10 min. The supernatants were used as whole cell extracts. Protein concentration was determined using the Bio-Rad protein determination method (Bio-Rad, Richmond, CA, USA). Equal amounts (50 μg) of proteins were boiled for 5 min and electrophoresed under reducing conditions on 6–12.5% (w/v) polyacrylamide gels. Proteins were electrophoretically transferred to a Hybond-polyvinylidene difluoride transfer membranes (Amersham Life Science, Buckinghamshire, UK), and incubated with the primary antibody, followed by peroxidase-linked secondary antibody. An Amersham ECL

chemiluminescent western system (Amersham) was used to detect secondary probes.

Statistical analysis

Data are expressed as mean \pm s.d. The Student's *t*-test was used to compare differences. Statistical significance was defined when *P* was <0.05.

References

- Aliberti J, Viola JP, Vieira-de-Abreu A, Bozza PT, Sher A, Scharfstein J. (2003). Bradykinin induces IL-12 production by dendritic cells: a danger signal that drives Th1 polarization. *J Immunol* **170**: 5349–5353.
- Bartholomae WC, Rininsland FH, Eisenberg JC, Boehm BO, Lehmann PV, Tary-Lehmann M. (2004). T cell immunity induced by live, necrotic, and apoptotic tumor cells. *J Immunol* **173**: 1012–1022.
- Glantzounis GK, Tsimoyiannis EC, Kappas AM, Galaris DA. (2005). Uric acid and oxidative stress. *Curr Pharm Des* **11**: 4145–4151.
- Ho LJ, Wang JJ, Shaio MF, Kao CL, Chang DM, Han SW et al. (2001). Infection of human dendritic cells by dengue virus causes cell maturation and cytokine production. *J Immunol* **166**: 1499–1506.
- Hu DE, Moore AM, Thomsen LL, Brindle KM. (2004). Uric acid promotes tumor immune rejection. *Cancer Res* **64**: 5059–5062.
- Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, Teraishi F et al. (2004). Telomerase-specific replication-selective virotherapy for human cancer. *Clin Cancer Res* **10**: 285–292.
- Lenaerts L, Naesens L. (2006). Antiviral therapy for adenovirus infections. *Antiviral Res* **71**: 172–180.
- Lindenmann J, Klein PA. (1967). Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus. *J Exp Med* **126**: 93–108.
- Manjili MH, Park J, Facciponte JG, Subjeck JR. (2005). HSP110 induces 'danger signals' upon interaction with antigen presenting cells and mouse mammary carcinoma. *Immunobiology* **210**: 295–303.
- Shi Y, Evans JE, Rock KL. (2003). Molecular identification of a danger signal that alerts the immune system to dying cells. *Nature* **425**: 516–521.
- Sijts A, Sun Y, Janek K, Kral S, Paschen A, Schadendorf D et al. (2002). The role of the proteasome activator PA28 in MHC class I antigen processing. *Mol Immunol* **39**: 165–169.
- Steinman RM, Turley S, Mellman I, Inaba K. (2000). The induction of tolerance by dendritic cells that have captured apoptotic cells. *J Exp Med* **191**: 411–416.
- Sun Y, Sijts AJ, Song M, Janek K, Nussbaum AK, Kral S et al. (2002). Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells. *Cancer Res* **62**: 2875–2882.
- Taki M, Kagawa S, Nishizaki M, Mizuguchi H, Hayakawa T, Kyo S et al. (2005). Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD'). *Oncogene* **24**: 3130–3140.
- Umeoka T, Kawashima T, Kagawa S, Teraishi F, Taki M, Nishizaki M et al. (2004). Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene. *Cancer Res* **64**: 6259–6265.
- Watanabe T, Hioki M, Fujiwara T, Nishizaki M, Kagawa S, Taki M et al. (2006). Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. *Exp Cell Res* **312**: 256–265.

Supplementary Information accompanies the paper on the Oncogene website (<http://www.nature.com/onc>).

Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus

Yuuri Hashimoto,¹ Yuichi Watanabe,¹ Yoshiko Shirakiya,¹ Futoshi Uno,² Shunsuke Kagawa,² Hitoshi Kawamura,¹ Katsuyuki Nagai,¹ Noriaki Tanaka,³ Horomi Kumon,² Yasuo Urata¹ and Toshiyoshi Fujiwara^{2,4}

¹Oncolys BioPharma, 3-16-33 Roppongi, Minato-ku, Tokyo 106-0031; ²Center for Gene and Cell Therapy, Okayama University Hospital, 2-5-1 Shikata-cho, Okayama 700-8558; ³Division of Surgical Oncology, Department of Surgery, Okayama University Graduate School of Medicine and Dentistry, 2-5-1 Shikata-cho, Okayama 700-8558, Japan

(Received June 25, 2007/Revised September 11, 2007/Accepted October 4, 2007/Online publication January 14, 2008)

The use of replication-selective tumor-specific viruses represents a novel approach for the treatment of neoplastic disease. We constructed an attenuated adenovirus, telomerase-specific replication-selective adenovirus (TRAD), in which the human telomerase reverse transcriptase promoter element drives the expression of the *E1A* and *E1B* genes linked with an internal ribosome entry site (IRES). Forty-eight hours after TRAD infection at a multiplicity of infection of 1.0, the cell viability of H1299 human lung cancer cells was consistently less than 50% and therefore this procedure could be used as a potency assay to assess the biological activity of TRAD. We also established a quantitative real-time polymerase chain reaction (PCR) analysis with consensus primers for either the adenovirus *E1A* or IRES sequence. The linear ranges of quantitation with *E1A* and IRES primers were 10^3 – 10^8 and 10^2 – 10^8 plaque-forming units/mL in the plasma, respectively. The PCR analysis demonstrated that the levels of *E1A* in normal tissues were more than 10^3 lower than in the tumors of A549 human lung tumor xenografts in *nu/nu* mice at 28 days after intratumoral injection. Our results suggest that the cell-killing assay against H1299 cells and real-time PCR can be used to assess the biological activity and biodistribution of TRAD in clinical trials. (*Cancer Sci* 2008; 99: 385–390)

The emerging fields of functional genomics and functional proteomics provide an expanding repertoire of clinically applicable targeted therapeutics.⁽¹⁾ Replication-selective oncolytic viruses provide a new platform for treatment of a variety of human cancers.^(2,3) Promising clinical trials have shown the antitumor potency and safety of mutant or genetically modified adenoviruses.^(4,5) We constructed previously an adenovirus vector, TRAD, in which the hTERT promoter element drives the expression of the *E1A* and *E1B* genes linked with an IRES. We showed that TRAD caused efficient selective killing of human cancer cells, but not normal cells.⁽⁶⁾ Many studies have demonstrated that the majority of malignant tumors express telomerase activity,⁽⁷⁾ suggesting that TRAD can potentially kill most human cancer cells.

TRAD can replicate and then lyse cancer cells, infect neighboring cancer cells, and subsequently induce oncolysis throughout the whole tumor mass *in vivo*. As preclinical models showed that TRAD could spread into the bloodstream, it is important to monitor carefully the amount of TRAD in the circulation after intratumoral injection of TRAD to avoid serious adverse events due to viremia. Although we used vector-specific primers that detected the p53 open reading frame–adenoviral DNA junction in a phase I clinical trial of a replication-deficient adenoviral vector expressing the wild-type p53 gene (Advexin),⁽⁸⁾ no appropriate method has been established to detect TRAD quantitatively. In addition, there is also a need for a procedure that can evaluate the biological activity of TRAD for clinical application.

In the present study, we characterized a potent antitumor viral agent, TRAD, to establish a biological assay and developed a

single quantitative PCR method that can be used to assess the number of viral genomes present in the plasma as well as tissues.

Materials and Methods

Cells and culture conditions. H1299 (a human non-small-cell lung cancer cell line), H460 (a human large-cell lung cancer cell line), A549 (a human lung adenocarcinoma cell line), LNCap (a human metastatic prostate carcinoma cell line), MKN28 and MKN45 (human gastric adenocarcinoma cell lines), PC-3 (a human prostate adenocarcinoma cell line), SW620 (a human colorectal carcinoma cell line), and TE8 and T.Tn (human esophagus squamous carcinoma cell lines) were propagated to monolayer cultures in RPMI-1640 supplemented with 10% FBS, and 100 units/mL PG and 100 μ g/mL SM. HeLa (a human cervical adenocarcinoma cell line), HepG2 (a human hepatocellular carcinoma cell line), Panc-1 (a human pancreatic epithelioid carcinoma cell line), and 293 (a transformed embryonic kidney cell line) were grown in DMEM containing high glucose (4.5 g/L) (high) with 10% FBS and PG/SM. HT-29 (a human colorectal adenocarcinoma cell line) was grown in McCoy's 5a with 10% FBS and PG/SM. MCF-7 (a human mammary gland adenocarcinoma cell line) was grown in Earle's Minimum Essential Medium with 10% FBS, PG/SM, and 2 mM L-glutamine. OST, SaOS2, and HOS (human osteosarcoma cell lines) were grown in DMEM (high) with 10% FBS and PG/SM. HSC-3 and HSC-4 (human tongue squamous carcinoma cell lines) were obtained from the Health Science Resources Bank (Osaka, Japan) and grown in DMEM (high) with 10% FBS and PG/SM. SCC-4 and SCC-9 (human tongue squamous carcinoma cell lines) were obtained from American Type Culture Collection (ATCC, Rockville, MD, USA) and grown in DMEM containing Nutrient Mixture (Ham's F-12) with 10% FBS, PG/SM, and 400 ng/mL hydrocortisone. U-2OS (a human osteosarcoma cell line) was obtained from ATCC and grown in McCoy's 5a with 10% FBS and PG/SM. NHLF was purchased from Takara Biomedicals (Kyoto, Japan) and cultured in the medium recommended by the manufacturer.

Recombinant adenoviruses. The recombinant replication-selective tumor-specific adenovirus vector TRAD was constructed and

*To whom correspondence should be addressed. E-mail: toshi_f@md.okayama-u.ac.jp
Abbreviations: ATCC, American Type Culture Collection; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; hTERT, human telomerase reverse transcriptase; ID₅₀, the multiplicity of infection that causes 50% growth inhibition; IRES, internal ribosome entry site; NHLF, normal human lung fibroblasts; MOI, multiplicity of infection; PCR, polymerase chain reaction; PFU, plaque-forming units; PG, penicillin; SM, streptomycin; TRAD, telomerase-specific replication-selective adenovirus; XTT, sodium 3'-(1-(phenylamino)carbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzene sulfonic acid hydrate.

characterized as described previously.^(6,9-11) The virus was purified by CsCl₂ step-gradient ultracentrifugation followed by CsCl₂ linear-gradient ultracentrifugation. The virus particle titer and infectious titer were determined spectrophotometrically and by plaque assay, respectively, in 293 cells.

Cell-viability assay. The XTT assay was carried out to measure cell viability. Cells were plated on 96-well plates at 1×10^5 cells/well 20 h before viral infection. HSC-4, SCC-4, and SCC-9 cells were then infected with TRAD at MOI of 0, 1, 10, and 50 PFU/cell. Other cell lines were infected with TRAD at MOI of 0, 0.1, 1, and 10 PFU/cell. Cell viability was determined at 1, 2, 3, and 5 days after virus infection using Cell Proliferation Kit II (Roche Molecular Biochemicals, Indianapolis, IN, USA) according to the protocol provided by the manufacturer. Using the cell viability data at 3 days after virus infection, we determined the TRAD ID₅₀ of each cell line.

Cell-killing assay. H1299 cells were plated at 5×10^4 cells/well on 24-well plates and infected with TRAD at MOI of 0, 0.01, 0.1, 1, and 10 PFU/cell. Forty-eight hours later, the number of cells in each well was counted. Experiments were carried out in triplicate for each MOI, and cell viability was assessed by the trypan blue dye exclusion assay.

Quantitative real-time PCR assay. Viral DNA from serially diluted viral stocks and tumor cells infected with TRAD were extracted using QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA), and quantitative real-time PCR assay for either the *E1A* gene or the IRES sequence was carried out using a LightCycler instrument and a LightCycler DNA Master SYBR Green I kit (Roche Molecular Biochemicals). Typical amplification mixes (20 μ L) contained 3 mM MgCl₂, 0.3 μ M of each primer for IRES or 0.5 μ M for *E1A*, and 2 μ L of $10 \times$ LightCycler FastStart DNA Master SYBR Green I. The sequences of the specific primers used in this experiment were: IRES, 5'-GAT TTT CCA CCA TAT TGC CG-3' and 5'-TTC ACG ACA TTC AAC AGA CC-3'; *E1A*, 5'-CCT GTG TCT AGA GAA TGC AA-3' and 5'-ACA GCT CAA GTC CAA AGG TT-3'. PCR amplifications were carried out in glass capillary tubes. PCR amplification for IRES began with a 10-min denaturation step at 95°C and then 40 cycles of denaturation at 95°C for 10 s, annealing at 60°C for 10 s, and extension at 72°C for 6 s. PCR amplification for *E1A* began with a 10-min denaturation step at 95°C and then 40 cycles of denaturation at 95°C for 10 s, annealing at 58°C for 15 s, and extension at 72°C for 8 s. Data analysis was carried out using LightCycler Software (Roche Molecular Biochemicals).

In vivo human tumor model. A549 human lung cancer cells (5×10^6 cells/mouse) were injected subcutaneously into the flank of 7- to 9-week-old female BALB/c *nu/nu* mice and permitted to grow to approximately 5–6 mm in diameter. At that stage, a 100- μ L solution containing 1×10^8 PFU of TRAD was injected into the tumor. The tumors and organs were harvested 28 and 70 days later and DNA was extracted from each tissue. To compare viral replication in the tumor and other normal organs, quantitative real-time PCR for the *E1A* gene was carried out using a LightCycler instrument. The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of Okayama University School of Medicine.

Statistical analysis. All data were expressed as mean \pm SD. Differences between groups were examined for statistical significance using Student's *t*-test. A *P*-value less than 0.05 denoted the presence of a statistically significant difference.

Results

In vitro cytopathic efficacy of TRAD in human cancer cell lines derived from different organs. To determine whether TRAD infection induces broad-spectrum selective cell lysis, 23 tumor cell lines derived from 11 different organs (head and neck, lung, esophagus, stomach, colon, liver, pancreas, breast, prostate,

uterus, and bone) were infected with TRAD at various MOI. Previous studies using a real-time reverse transcription-PCR method have demonstrated that these cell lines express detectable levels of hTERT mRNA.^(6,9) Cytotoxicity was then assessed using the XTT cell-viability assay over 5 days after infection. As shown in Figure 1a, TRAD infection induced cell death in all cell lines except T.Tn esophageal cancer cells in a dose-dependent manner. Calculated ID₅₀ values confirmed that all cell lines except T.Tn could be killed efficiently by TRAD at an MOI of less than 25 (Fig. 1b). These results suggest the broad-spectrum antitumor potency of TRAD.

Establishment of a standard assay to assess the biological activity of TRAD. H1299 human lung cancer cells and LNCap human prostate cancer cells were the most sensitive cell lines to TRAD-induced cell death (Fig. 1b). Accordingly, we used H1299 cells to evaluate the biological activity of TRAD. To test whether the selective replication of TRAD translates into selective oncolysis, we compared the cytopathic effects of TRAD in H1299 cells and NHLF at 5 days after infection. The dose-response curve of the relative cell viability in H1299 cells was shifted to the left compared to that in NHLF, suggesting that TRAD killed H1299 cells 10^2 – 10^3 more efficiently than NHLF (Fig. 2a).

We next determined the minimal dose of TRAD that could induce more than 50% of cell death in H1299 cells. As shown in Figure 2b, the cell viability of H1299 cells was less than 40% at 48 h after their infection with TRAD at a MOI of 1.0, but was 60% after infection with a MOI of 0.1. We also confirmed that H1299 cells at various passages (5th to 20th after purchase from ATCC) could be killed by TRAD in a similar fashion (data not shown). Therefore, TRAD could be considered biologically active, if TRAD at a MOI of 1 reduces the cell viability of H1299 cells by more than 50% at 48 h after infection. To estimate the utility of this assay, we examined the biological activity of heat-inactivated TRAD. Infection with intact TRAD at a MOI of 10 induced approximately 90% reduction in H1299 cell viability at 48 h after infection, whereas the antitumor activity was completely inhibited when it was preheated at 56°C for 5 or 10 min (Fig. 2c).

Development of quantitative PCR assay to detect copy numbers of TRAD. We used real-time PCR for quantitative detection of TRAD. Oligonucleotide primers were designed to achieve DNA amplification of the adenoviral *E1A* or IRES sequences in the TRAD genome (Fig. 3a). To generate accurate standard curves, TRAD at a known concentration was serially diluted and used as a template for real-time PCR analysis. Detection of IRES and *E1A* genome copies was achieved consistently and reproducibly by the PCR cycle values used. A linear relationship could be obtained between the number of cycles and the log₁₀ dilution when 10^2 – 10^8 IRES copies and 10^3 – 10^8 *E1A* copies were assayed. Regression analysis of IRES and *E1A* curves resulted in very high correlation coefficients (0.99 and 1.00, respectively) for these concentration ranges (Fig. 3b). In addition, the dilution of TRAD virus in the plasma did not affect the sensitivity and dynamic ranges of quantification (Fig. 3b), suggesting that this method can be used to detect TRAD in the blood circulation.

In vitro quantification and replication monitoring of TRAD in infected human tumor and normal cells. We next examined the replication ability of TRAD in different cell lines by measuring the relative amounts of IRES and *E1A* copy numbers. LNCap and NHLF cells were harvested at the indicated time points over 5 and 7 days, respectively, after infection with TRAD, and subjected to quantitative real-time PCR analysis using IRES and *E1A* primers. The ratios were normalized by dividing the value of cells obtained at 2 h after viral infection. As shown in Figure 4a, TRAD replicated 10^3 – 10^4 by 5 days after infection; its replication, however, was attenuated to less than 10^3 in normal NHLF cells. We previously reported that TRAD could replicate 10^3 – 10^6 by 3 days after infection in H1299 cells;^(6,10) however, as




Fig. 2. Antitumor effects of telomerase-specific replication-selective adenovirus (TRAD) on H1299 non-small-cell lung cancer cells *in vitro*. (a) Effects of various concentrations of TRAD on H1299 cancer cells and normal human lung fibroblasts (NHLF) assessed at 5 days after treatment with XTT assay. Results are expressed as the percentage of untreated control. (b) H1299 cells were cultured as monolayers in triplicate in 24-well culture plates, infected with TRAD at the indicated multiplicities of infection (MOI), and assessed for cell viability 48 h after infection. Mock-infected cells were used as a control. (c) H1299 cells were plated on 96-well plates and infected with 10 MOI of TRAD heated at 56°C for 5 or 10 min, or non-treated TRAD. An XTT assay was carried out at 3 days after virus infection. Mock-infected cells were used as a control. Data represent the mean \pm SD of triplicate experiments. PFU, plaque-forming units; XTT, sodium 3'-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro) benzene sulfonic acid hydrate; VP, virus particles.




Fig. 3. Detection of normal human lung fibroblasts (TRAD) using quantitative polymerase chain reaction (PCR) assay. (a) Schematic diagram of the DNA structure of TRAD. TRAD contains the human telomerase reverse transcriptase (hTERT) promoter sequence inserted into the adenovirus genome to drive transcription of the *E1A* and *E1B* bicistronic cassette linked by the internal ribosome entry site (IRES) structure. Sites to which PCR primers (IRES and *E1A*) were targeted are indicated. Two primer pairs of IRES and *E1A* were designed to detect the TRAD genome. (b) Standard calibration curves of threshold cycle values and copy numbers are shown using serial dilution of TRAD virus stock. The coefficient of correlation (r^2) and slope are indicated for assays with IRES and *E1A* primers. ITR, inverted terminal repeats; PFU, plaque-forming units.

LNCap cells were more sensitive to TRAD-mediated cytotoxicity than H1299 cells (Fig. 1a), viral replication reached a plateau phase around 10^4 when LNCap cells started to die. Moreover, PCR targeting IRES and *E1A* showed similar replication profiles for TRAD in MCF-7 human breast cancer cells (Fig. 4b). To monitor the long-term viral replication, MCF-7 cells that were less sensitive to the cytopathic effect of the virus were used.

In vivo determination of TRAD genomes in tissue samples after intratumoral injection. To evaluate selective replication of TRAD *in vivo*, we examined mouse tissues, including implanted tumors, for the presence of viral DNA by quantitative real-time PCR, following intratumoral viral injection. Mice with established subcutaneous A549 human lung tumor xenografts received a single intratumoral injection of 1×10^8 PFU of TRAD, and were killed 28 or 70 days after injection. To obtain the sufficient amounts of tumor tissues for analysis, we chose to use A549 cells. Our preliminary experiments demonstrated that intratumoral administration of TRAD suppressed tumor growth significantly compared with mock-treated tumors at 42 days after initiation of treatment ($P < 0.05$); however, the *in vivo* antitumor effect against A549 tumors was less than that against H1299 or LNCap

tumors (data not shown). Although *E1A* DNA was detected in serum and some normal tissues examined (brain, heart, lung, ovary, liver, uterus, kidneys, bladder, colon, and axillary and mesenteric lymph nodes), tumors injected with TRAD contained at least 1000-fold more *E1A* copies (Fig. 5). These results suggest that quantitative real-time PCR allows detection and quantification of the number of TRAD genomes present in tissue samples after intratumoral injection of TRAD *in vivo*.

Discussion

Oncolytic viruses have been developed as anticancer agents based on the advantage of selective killing of tumor cells by controlled replication of the virus in the tumors, resulting in minimal undesired effects on normal cells.⁽²⁾ Furthermore, amplified viruses can infect adjacent tumor cells as well as reach distant metastatic tumors through the blood circulation. Although this might be a potential advantage of oncolytic viruses, systemic dissemination of large amounts of virus may induce virus-related symptoms including fever, diarrhea, pneumonia, and hepatitis, eventually leading to death. Therefore, virus shedding and distribution have to be evaluated by appropriate and suitable methods. In addition,




Fig. 4. Quantitative measurement of viral DNA replication in human cancer and normal cells *in vitro* by quantitative polymerase chain reaction (PCR) assay. (a) LNCap human prostate cancer cells and normal human lung fibroblast (NHLF) cells were infected with telomerase-specific replication-selective adenovirus (TRAD) at a multiplicity of infection (MOI) of 1 for 2 h. Following the removal of virus inoculum, cells were further incubated for the indicated periods of time, and then subjected to the real-time quantitative PCR assay. The amounts of viral internal ribosome entry site (IRES) and E1A copy number was defined as the fold increase for each sample relative to that at 2 h (2 h equals 1). (b) MCF-7 human breast cancer cells were infected with TRAD at a MOI of 1 and subjected to the PCR assay at the indicated time points. The relative TRAD DNA levels detected by IRES and E1A primers were plotted.




Fig. 5. Spread and replication of telomerase-specific replication-selective adenovirus (TRAD) following intratumoral administration in *nu/nu* mice transplanted with A549 tumor cells. A549 tumor cells were injected subcutaneously into the right flank of mice at 5×10^6 cells/mouse. Mice received intratumoral injection of 1×10^8 plaque-forming units of TRAD when the tumor reached a size of approximately 5–6 mm in diameter. DNA was extracted from the subcutaneous tumor and various tissues of *nu/nu* mice at 28 or 70 days after infection. Viral DNA was detected by quantitative polymerase chain reaction amplification of the adenoviral E1A sequence. The amounts of TRAD genome were defined as viral E1A copy number per μg DNA. LN, lymph nodes.

to avoid unexpected infectious disease due to viral overdose, we need assays that accurately detect the biological activity of viruses. In the present study, for clinical trials of TRAD, we developed an assay designed to estimate the biological activity of TRAD and to detect the copy number of TRAD in the plasma as well as tissues.

Although telomerase-specific TRAD exhibited a broad cytopathic effect against human cancer cell lines of different tissue origins, a human non-small-cell lung cancer cell line, H1299, was chosen for the biological assay of TRAD. H1299 was one of the most sensitive cell lines to TRAD-mediated cell death ($\text{ID}_{50} = 0.94$ MOI) and could be killed efficiently by TRAD infection in a dose-dependent fashion (Fig. 1). Because H1299 cells can be obtained from ATCC, they can be used in clinical laboratories to assess the biological activity of TRAD with a qualified standard protocol. In addition, although adenoviral E1B-55 kDa protein is known to bind to the tumor suppressor p53 protein,⁽¹²⁾ H1299 cells are p53-null and therefore the interaction of E1B-55 kDa with p53, which in turn results in transcriptional modulation, can be ignored in this cell line. Thus, H1299 is considered an appropriate cell line for assessment of TRAD activity in certain preparations. In the present study, we considered TRAD to be active when the viability of H1299 cells was reduced by more than 50% at 48 h after TRAD infection at an MOI of 1. Using this biological assay, we confirmed that heat

treatment of aliquots of TRAD at 56°C for 5 min is sufficient to inactivate its antitumor potential (Fig. 2c). These results advocate the use of the H1299 cell-based cytotoxicity assay as a standard method for quantitative assessment of the biological activity of TRAD in virus stocks for clinical trials.

Various biological methods, such as determination of infectious units in plaque assays, have been used routinely in clinical trials to monitor viral loads in the peripheral circulation.⁽⁸⁾ These methods are useful for evaluating safety because the viral titers directly reflect the infectivity of viruses. However, because the plaque assay consists of labor-intensive and time-consuming steps, real-time monitoring of the biodistribution of the virus might be difficult. Here we described the development of a quantitative real-time PCR assay that can accurately quantify genome copy numbers of TRAD over a large linear range. Using primers targeting TRAD-specific sequences, such as adenoviral E1A and IRES, real-time PCR could accurately detect the number of TRAD genomes in the plasma as well as in the cells (Figs 3,4). The assay showed that TRAD replicated even in NHLF, although the level was much lower than that in tumor cells. It is usually difficult to maintain the normal cells primarily isolated from human tissues such as human hepatocytes in the culture; however, commercially available NHLF could be cultured for several passages, suggesting that NHLF may have some characteristics different from primary isolated normal cells, including

telomerase activity. We also found that the number of viral genomes could be measured in genomic DNA purified from tissues of mice *in vivo* after injection of TRAD into the xenografts (Fig. 5). Although viral DNA could be detected even in normal tissues 70 days after intratumoral injection of TRAD, the absence of infectious virus as assessed by the plaque assay suggests that there are only DNA fragments in tissues. Our preliminary experiments have demonstrated that DNA could be isolated from tumors as small as 5 mm in diameter (data not shown). Therefore, the real-time PCR method with E1A and IRES primers permits rapid and quantitative detection of TRAD DNA in clinical samples.

We have shown recently the antiviral activity of cidofovir against TRAD *in vitro*. Cidofovir is an acyclic nucleoside phosphonate with potent broad-spectrum anti-DNA viral activity and has been approved for the treatment of many types of viruses, including cytomegalovirus and adenovirus.⁽¹³⁾ Although viremia after TRAD administration is extremely rare because of the anti-adenovirus antibodies expected to be present in most patients, a

real-time PCR-based pharmacokinetic assay can allow the early detection of disseminated virus, and thus its use could provide an indication for commencement of cidofovir treatment in clinical trials.

In summary, we have established a fast, reliable, and sensitive assay to assess the biological activity of TRAD *in vitro* and to detect the viral genome in the plasma as well as tissues *in vivo*. A phase I clinical trial of TRAD targeting advanced solid tumors is currently underway in the USA following the approval of the Food and Drug Administration. Such an assay has been used in this ongoing trial and the data will be analyzed in the near future for the assessment of the safety, efficacy, and bio-distribution of TRAD.

Acknowledgments

This work was supported in part by grants from the Ministry of Education, Science, and Culture, Japan, and by grants from the Ministry of Health and Welfare, Japan.

References

- 1 Kohn EC, Lu Y, Wang H *et al*. Molecular therapeutics: promise and challenges. *Semin Oncol* 2004; **31**: 39–53.
- 2 Hawkins LK, Lemoine NR, Kim D. Oncolytic biotherapy: a novel therapeutic platform. *Lancet Oncol* 2002; **3**: 17–26.
- 3 Chiocca EA. Oncolytic viruses. *Nat Rev Cancer* 2002; **2**: 938–50.
- 4 Reid T, Galanis E, Abbruzzese J *et al*. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. *Cancer Res* 2002; **62**: 6070–9.
- 5 Hamid O, Varterasian ML, Wadler S *et al*. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. *J Clin Oncol* 2003; **21**: 1498–504.
- 6 Kawashima T, Kagawa S, Kobayashi N *et al*. Telomerase-specific replication-selective virotherapy for human cancer. *Clin Cancer Res* 2004; **10**: 285–92.
- 7 Kim NW, Piatyszek MA, Prowse KR *et al*. Specific association of human telomerase activity with immortal cells and cancer. *Science* 1994; **266**: 2011–15.
- 8 Fujiwara T, Tanaka N, Kanazawa S *et al*. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. *J Clin Oncol* 2006; **24**: 1689–99.
- 9 Umeoka T, Kawashima T, Kagawa S *et al*. Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene. *Cancer Res* 2004; **64**: 6259–65.
- 10 Taki M, Kagawa S, Nishizaki M *et al*. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD'). *Oncogene* 2005; **24**: 3130–40.
- 11 Watanabe T, Hioki M, Fujiwara T *et al*. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent TRAD in human lung cancer cells. *Exp Cell Res* 2006; **312**: 256–65.
- 12 Cathomen T, Weitzman MD. A functional complex of adenovirus proteins E1B-55kDa and E4orf6 is necessary to modulate the expression level of p53 but not its transcriptional activity. *J Virol* 2000; **74**: 11 407–12.
- 13 Ouchi M, Kawamura H, Nagai K, Urata Y, Fujiwara T. Antiviral activity of cidofovir against telomerase-specific replication-competent adenovirus, Telomelysin (OBP-301). *Mol Ther* 2007; **15** (Suppl 1): S173.

悪性腫瘍に対するウイルス製剤

—Telomelysin の開発と臨床応用の可能性—

岡山大学医学部・歯学部附属病院 遺伝子・細胞治療センター助教授* / 同大学大学院医歯学総合研究科 消化器・腫瘍外科学教授**

藤原俊義*・田中紀章**

はじめに

最近の遺伝子工学の進歩により、ウイルスゲノムを改変し、その安全性を高めたり特殊な機能を増強することが可能となってきた。最初の試みは、ウイルスゲノムの一部を欠損させることで増殖性をおさえ、治療遺伝子を発現させることで安全性と機能を確保した。このウイルスベクターを用いた「遺伝子治療」がヒトに応用されてから、すでに10年以上が経過している。多くの非増殖型ウイルスベクターが臨床応用され、特定の患者群に対しては有用性が認められた^{1,2)}。しかし、*in vivo*における標的組織への遺伝子導入効率の限界などから、かならずしも前臨床試験で期待された臨床効果が認められているとはいえない。

ウイルスは、本来ヒトの細胞に感染、増殖し、その細胞をさまざまな機序により破壊する。その増殖機能に選択性を付加することにより、ウイル

スを癌細胞のみを傷害する治療用製剤として用いることができる(図1)³⁾。アデノウイルスはその構造がもっともよく研究されているウイルスの一つであり、非増殖型のものが多くの遺伝子治療プロトコルで使用されることによって、その安全性に関する情報が蓄積されてきている⁴⁾。

本稿では、テロメラーゼ活性依存性に癌細胞で選択的に増殖して細胞死を誘導するアデノウイルスの開発の現況について紹介し、その抗腫瘍医薬品としての臨床応用の可能性を考察する。

アデノウイルスの特徴と制限増殖能の分子機構

ヒトのアデノウイルスはエンベロープをもたない30~38kbサイズの二重鎖DNAウイルスであり、41種の亜型が存在し、6群に分類されている。遺伝子導入用ベクターの基本骨格としてよく用いられるアデノウイルス5型は、幼児期に気道感染




図1 癌細胞での選択的なウイルス増殖と細胞死誘導³⁾

によりいわゆる「かぜ」症状を起こす原因ウイルスの一つであり、アメリカでは30年以上の間、約100万人の兵士に対しワクチンとしてアデノウイルスが投与され、その後重篤な副作用の報告もなかったという実績をもつ。

アデノウイルスゲノムはその構造が詳細に解析されており、ウイルスの複製増殖のきわめて初期(immediate-early, IE)に働く遺伝子群、初期(early, E)に働く遺伝子群、および後期(late, L)に関与する遺伝子群に分けられる⁵⁾。

現在、アデノウイルスに癌細胞における特異的な増殖機能を発揮させるために、大きく2つの方法が開発されている。最初の試みは、アデノウイルスの初期遺伝子に特定の変異あるいは欠失を加えることにより、癌細胞の生物学的な特殊性に基づいた制限増殖性を期待する方法である。E1B初期遺伝子の55 kDaを欠損した変異ウイルスであるOnyx-015が代表的であり、いくつかの第I相および第II相臨床試験はすでに終了している^{6,7)}。第2の試みは、腫瘍特異的および臓器特異的なプロモーターによる初期遺伝子の転写制御をメカニズムとして、癌細胞特異的あるいは特定の臓器由来の癌細胞に特異的な制限増殖性を付加する方法である。この際、さまざまな発生母地をもつ広い範囲の癌に適用するためには、より汎用性を有するプロモーターを用いる必要がある。

テロメラーゼ活性とhTERT遺伝子

染色体DNA末端の短い塩基配列(TTAGGG)の繰り返しで構成されるテロメアは、細胞増殖に伴い、次第に短縮し細胞に老化(replicative senescence)を引き起こす。このテロメアの短縮は発癌の抑制機構であり、前癌状態にある細胞が老化に陥り死滅することで癌化が阻止されている。逆に、無制限の増殖能を有する癌細胞はテロメアを維持する分子機構を獲得しており、代表的なものがテロメラーゼの活性化である。テロメラーゼは、染色体の3'末端にTTAGGG配列を伸長しテロメア長を保つ作用をもつリボ核酸蛋白酵素であり、触媒サブユニットhTERT(human telomerase

reverse transcriptase)と鋳型となるRNAサブユニット(hTR)から構成される。テロメラーゼ活性はhTERT遺伝子発現レベルと相関し、またhTERT遺伝子導入によりテロメラーゼ活性を誘導することができることから、hTERT分子がテロメラーゼ活性を制御していると考えられる⁸⁾。テロメラーゼは、きわめて多くの癌細胞でその活性の上昇が明らかになっており⁹⁾、癌細胞ではhTERT遺伝子の発現制御を行っているhTERTプロモーターのスイッチがオンになると考えられる。

テロメラーゼ特異的腫瘍融解アデノウイルスの構造と機能

前立腺癌に特異的なPSA¹⁰⁾をはじめとして、AFP¹¹⁾やMUC-1¹²⁾など、さまざまなプロモーターによる癌特異的に増殖するアデノウイルスが開発されており、それぞれのプロモーター機能に対応する癌細胞においてはその有効性が示されている。しかし、より広範な癌を対象とするために、筆者らはアデノウイルスの増殖に必要なE1A遺伝子とE1B遺伝子をIRES配列で結合した発現カセットをhTERTプロモーターにより選択的に発現する、テロメラーゼ特異的腫瘍融解ウイルスTelomelysin(開発コード:OBP-301)を作製した¹³⁾(図2-A)。

多くの制限増殖型アデノウイルスがE1A遺伝子のみを選択的プロモーターで制御しているのに比べて、TelomelysinではE1AおよびE1BをいずれもhTERTプロモーターの制御下におくことで、より癌細胞での特異性が確保できている。実際に、Telomelysin感染後3日までに、各種癌細胞においては $10^5 \sim 10^8$ 倍のウイルス複製増殖が認められたが、正常細胞では100~1,000倍におさえられていた。肺癌、大腸癌、胃癌、食道癌、頭頸部癌、乳癌、肝癌、膵癌、前立腺癌、子宮頸癌、卵巣癌などのヒト由来各種癌細胞では、1~10 multiplicity of infection(MOI)のTelomelysin感染で3~5日以内にcytopathic effect(CPE)が誘導され、完全な細胞死が観察された(図2-B)。ヌードマ




図 2 Telomelysin (OBP-301) の構造と抗腫瘍活性¹³⁾

A : Telomelysin は、ウイルスの増殖に必要な E1 と E3 領域が除去されている第一世代のアデノウイルスベクターを基本骨格としている。hTERT プロモーターと IRES 配列で結合した E1A, E1B 遺伝子よりなる増殖カセットが、相同組み換えによりアデノウイルス 5 型由来のベクターの欠損した E1 部分に組み込んである。

B : ヒト大腸癌細胞 SW620, ヒト肺癌細胞 H1299, A549, および正常ヒト肺線維芽細胞 (NHLF) に Telomelysin を 0, 0.01, 0.1, 1 MOI で感染させ、経日的に細胞数をカウントし、生細胞数の比率で示した。* $p < 0.01$ 。

ウス背部皮下に移植したヒト肺癌腫瘍に、 10^7 plaque forming units (PFU) という低濃度の Telomelysin を腫瘍内局所投与したところ、無治療の腫瘍や非増殖型のコントロール・アデノウイルスの投与に比較して有意な増殖抑制が認められ (図 3-A)¹³⁾, さらに Telomelysin は血中を循環し、遠隔部位の腫瘍内でも増殖していることが、DNA-

PCR 解析や E1A 蛋白質に対する免疫染色などにより確認された。これらの結果は、原発腫瘍内投与した Telomelysin による微小転移巣の治療の可能性を示唆している。

Telomelysin は、診断用医薬品としても応用可能である。すなわち、オワンクラゲ由来の蛍光遺伝子 GFP (green fluorescence protein) を組み込ん